3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
9
Terminated
6
Recruiting
5
Unknown
3
Withdrawn
1
Suspended
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Dermatologic
6
Other hematologic neoplasm
5
Lymphoid
2
Thoracic
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Ovarian Cancer Metastatic
1
Interventions
Paclitaxel
20
Carboplatin
20
Bevacizumab
13
Radiotherapy
12
Cisplatin
11
Cyclophosphamide
8
olaparib
6
niraparib
6
Taxes
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
Gemcitabine
5
Biopsy
5
talazoparib
4
dostarlimab
4
aldesleukin
4
Specimen Handling
4
Fulvestrant
4
Doxorubicin
4
fludarabine
3
atezolizumab
3
Topotecan
3
Radiation
3
NVP-BKM120
3
Methods
3
Metformin
3
Letrozole
3
Hyperthermic Intraperitoneal Chemotherapy
3
Early Intervention, Educational
3
Colposcopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Interleukin-2
×
Gynecologic
×
Clear all
NCT04389229
2020-12-16
OVSTAR
Immetacyte Ltd
Phase 1/2
Withdrawn